(1S)-6-氧杂螺[2.5]辛烷-1-羧酸 | 909406-97-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 中文名称: (1S)-6-氧杂螺[2.5]辛烷-1-羧酸
• 英文名称: (S)-6-oxaspiro[2.5]-octane-1-carboxylic acid
• 英文别名: (1S)-6-Oxaspiro[2.5]octane-1-carboxylic acid；(2S)-6-oxaspiro[2.5]octane-2-carboxylic acid
• CAS: 909406-97-9
• 化学式: C₈H₁₂O₃
• 分子量: 156.181
• InChiKey: FGFLMSPWCDFJRM-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1S)-6-氧杂螺[2.5]辛烷-1-羧酸 在 N,N'-羰基二咪唑 、 氨 、 水 作用下， 以 乙酸乙酯 为溶剂， 反应 22.0h， 生成 (S)-6-oxa-spiro[2.5]octane-1-carboxamide
  参考文献：
  名称：

  WO2006/95020

  摘要：

  公开号：
• 作为产物：
  描述：

  (R)-4-benzyl-3-((S)-6-oxaspiro[2.5]octane-1-carbonyl)oxazolidin-2-one 生成 (1S)-6-氧杂螺[2.5]辛烷-1-羧酸
  参考文献：
  名称：

  WO2007/31558

  摘要：

  公开号：

文献信息

• Heterocyclic-substituted alkanamides as therapeutic compounds
  申请人：Speedel Experimenta AG

  公开号：EP1958666A1

  公开（公告）日：2008-08-20

  Use of compounds of the general formula (I) and pharmaceutically acceptable salt thereof, in which R1 and R2 have the definitions illustrated in detail in the description, as beta-secretase, cathepsin D, plasmepsin II and/or HIV protease inhibitors.

  使用一般式（I）及其药用盐的化合物，其中R1和R2的定义在描述中详细说明，作为β-分泌酶、半胱氨酸蛋白酶D、血浆蛋白酶II和/或HIV蛋白酶抑制剂。
• Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors
  申请人：Herold Peter

  公开号：US20080176947A1

  公开（公告）日：2008-07-24

  Compounds of the general formula (I) in which the meanings of the substituents R 1 and R 2 are as stated in claim 1 , have renin-inhibiting properties and can be used as medicines.

  通式（I）中，取代基R1和R2的含义如权利要求1所述的化合物具有抑制肾素的性质，可用作药物。
• 5-Amino-4-Hydroxy-7-(Imidazo [1,2-A] Pyridin-6-Ylmethyl)-8-Methyl-Nonamide Derivatives and Related Compounds as Renin Inhibitors for the Treatment of Hypertension
  申请人：HEROLD Peter

  公开号：US20100063087A1

  公开（公告）日：2010-03-11

  Compounds of the general formula (I) or its salt or a compound in which one or more atoms are replaced by their stable, nonradio-active isotopes, in particular its pharmaceutically acceptable salt; in which X is —CH 2 —; R is a mono- to tetra-substituted, mono- or bicyclic, unsaturated heterocyclic radical having 1 to 4 nitrogen atoms, R 2 is C 1-6 alkyl or C 3-6 cycloalkyl; R 3 is independently of one another H, C 1-6 alkyl, C 1-6 alkoxycarbonyl or C 1-6 alkanoyl; R 4 is C 2-6 alkenyl, C 1-6 alkyl, unsubstituted or substituted aryl-C 1-6 alkyl or C 3-8 cycloalkyl; R 5 is -L m -R ; L is C 1-6 alkylene which is optionally substituted by 1-4 halogen, or a linker: formula (II) n=0, 1 or 2; m=0 or 1; R 6 is a radical composed of 2 cyclic systems selected from bicyclo[x.y.z]alkyl, spiro[o.p]alkyl, mono- or bioxabicyclo[x.y.z]alkyl or mono- or bioxaspiro[o.p]alkyl, all of which may be substituted by 1-3 substituents selected from C 1-6 alkyl, C 1-6 alkoxy, cyano, halogen, C 1-6 alkoxy- C 1-6 alkyl, hydroxy-C 1-6 alkyl or dialkylamino, or if m=0: is also saturated C 3-8 heterocyclyl which comprises 1-2 oxygen atoms, substituted by 1-3 substituents selected from C 1-6 alkyl, C 1-6 alkoxy, cyano, halogen, C 1-6 alkoxy-C 1-6 alkyl, hydroxy-C 1-6 alkyl or dialkylamino, or if m=1: is also saturated C 3-8 heterocyclyl which comprises 1-2 oxygen atoms, optionally substituted by 1-3 substituents selected from C 1-6 alkyl, C 1-6 alkoxy, cyano, halogen, C 1-6 -alkoxy-C 1-6 alkyl, hydroxy-C 1-6 alkyl or dialkylamino; have renin-inhibiting properties and can be used as medicines for the treatment of hypertension.

  通式（I）的化合物或其盐或其中一个或多个原子被其稳定的非放射性同位素替换的化合物，特别是其药学上可接受的盐；其中X为-CH2-；R为1至4个氮原子的单取代、双取代、三取代或四取代的单环或双环不饱和杂环基，R2为C1-6烷基或C3-6环烷基；R3独立地为H、C1-6烷基、C1-6烷氧羰基或C1-6酰基；R4为C2-6烯基、C1-6烷基、未取代或取代的芳基-C1-6烷基或C3-8环烷基；R5为-Lm-R；L为C1-6烷基，可选地被1-4个卤素取代，或为连接基：通式（II）n=0、1或2；m=0或1；R6为由自行选择的2个环系统组成的基，所述环系统选择自双环[x.y.z]烷基、螺[O.P]烷基、单环或双氧杂双环[x.y.z]烷基或单环或双氧杂螺[O.P]烷基，所有这些基都可以被1-3个取代基所取代，所述取代基选择自C1-6烷基、C1-6烷氧基、氰基、卤素、C1-6烷氧基-C1-6烷基、羟基-C1-6烷基或二烷基氨基，或如果m=0：还是饱和的C3-8杂环基，其中包括1-2个氧原子，被1-3个取代基所取代，所述取代基选择自C1-6烷基、C1-6烷氧基、氰基、卤素、C1-6烷氧基-C1-6烷基、羟基-C1-6烷基或二烷基氨基，或如果m=1：还是饱和的C3-8杂环基，其中包括1-2个氧原子，可选地被1-3个取代基所取代，所述取代基选择自C1-6烷基、C1-6烷氧基、氰基、卤素、C1-6烷氧基-C1-6烷基、羟基-C1-6烷基或二烷基氨基；具有抑制肾素的性质，可用作治疗高血压的药物。
• 5-amino-4-hydroxy-7-(imidazo [1,2-A] pyridin-6-ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension
  申请人：Novartis AG

  公开号：US08071651B2

  公开（公告）日：2011-12-06

  Compounds of the general formula (I) or its salt or a compound in which one or more atoms are replaced by their stable, nonradio-active isotopes, in particular its pharmaceutically acceptable salt; in which X is —CH2—; R is a mono- to tetra-substituted, mono- or bicyclic, unsaturated heterocyclic radical having 1 to 4 nitrogen atoms, R2 is C1-6alkyl or C3-6cycloalkyl; R3 is independently of one another H, C1-6alkyl, C1-6alkoxycarbonyl or C1-6alkanoyl; R4 is C2-6alkenyl, C1-6alkyl, unsubstituted or substituted aryl-C1-6alkyl or C3-8cycloalkyl; R5 is -Lm-R6; L is C1-6alkylene which is optionally substituted by 1-4 halogen, or a linker: formula (II) n=0, 1 or 2; m=0 or 1; R6 is a radical composed of 2 cyclic systems selected from bicyclo[x.y.z]alkyl, spiro[o.p]alkyl, mono- or bioxabicyclo[x.y.z]alkyl or mono- or bioxaspiro[o.p]alkyl, all of which may be substituted by 1-3 substituents selected from C1-6alkyl, C1-6alkoxy, cyano, halogen, C1-6alkoxy-C1-6alkyl, hydroxy-C1-6alkyl or dialkylamino, or if m=0: is also saturated C3-8heterocyclyl which comprises 1-2 oxygen atoms, substituted by 1-3 substituents selected from C1-6alkyl, C1-6alkoxy, cyano, halogen, C1-6alkoxy-C1-6alkyl, hydroxy-C1-6alkyl or dialkylamino, or if m=1: is also saturated C3-8heterocyclyl which comprises 1-2 oxygen atoms, optionally substituted by 1-3 substituents selected from C1-6alkyl, C1-6alkoxy, cyano, halogen, C1-6-alkoxy-C1-6alkyl, hydroxy-C1-6alkyl or dialkylamino; have renin-inhibiting properties and can be used as medicines for the treatment of hypertension.

  通式(I)或其盐或其中一个或多个原子被它们的稳定的非放射性同位素所替代的化合物，特别是其药学上可接受的盐；其中X是—CH2—；R是一个单取代至四取代、单环或双环、不饱和的杂环基团，含1至4个氮原子；R2是C1-6烷基或C3-6环烷基；R3是独立的H、C1-6烷基、C1-6烷氧羰基或C1-6酰基；R4是C2-6烯基、C1-6烷基、未取代或取代的芳基-C1-6烷基或C3-8环烷基；R5是-Lm-R6；L是可选地被1-4个卤素取代的C1-6烷基，或连接物：通式(II)，n=0、1或2；m=0或1；R6是由选自双环[x.y.z]烷基、螺[ο.p]烷基、单或双氧杂双环[x.y.z]烷基或单或双氧杂螺[ο.p]烷基的2个环系统组成的基团，所有这些基团都可以被选自C1-6烷基、C1-6烷氧基、氰基、卤素、C1-6烷氧基-C1-6烷基、羟基-C1-6烷基或二烷基氨基的1-3个取代基所取代，或如果m=0：还包括由1-2个氧原子组成、被选自C1-6烷基、C1-6烷氧基、氰基、卤素、C1-6烷氧基-C1-6烷基、羟基-C1-6烷基或二烷基氨基的1-3个取代基所取代的饱和C3-8杂环基团，或如果m=1：还包括由1-2个氧原子组成、可选地被选自C1-6烷基、C1-6烷氧基、氰基、卤素、C1-6烷氧基-C1-6烷基、羟基-C1-6烷基或二烷基氨基的1-3个取代基所取代的饱和C3-8杂环基团；具有抑制肾素的性质，可用作治疗高血压的药物。
• [EN] ANTAGONISTS OF MRGX2<br/>[FR] ANTAGONISTES DE MRGX2
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2022152853A1

  公开（公告）日：2022-07-21

  This application relates to compounds of Formula I which are antagonists of MrgX2 (Mas-related Gene X2) and thus are useful as therapeutic agents, specifically therapeutic agents for use in the treatment of chronic spontaneous urticaria, mastocytosis, cold urticaria, atopic dermatitis, rosacea, Crohn's disease, ulcerative colitis, irritable bowel syndrome, rheumatoid arthritis, fibromyalgia, nasal polyps, neuropathic pain, inflammatory pain, chronic itch, drug- induced anaphylactoid reactions, metabolic syndrome, oesophagus reflux, asthma, cough, or migraine.

  本发明涉及公式I的化合物，其为MrgX2（Mas相关基因X2）的拮抗剂，因此可作为治疗剂使用，具体用于治疗慢性自发性荨麻疹、肥大细胞增多症、寒冷性荨麻疹、特应性皮炎、酒渣鼻、克罗恩病、溃疡性结肠炎、肠易激综合征、类风湿性关节炎、纤维肌痛、鼻息肉、神经痛、炎症性疼痛、慢性瘙痒、药物诱导的过敏反应、代谢综合征、食道反流、哮喘、咳嗽或偏头痛的治疗剂。